MarginsXMarginsX
Home › Markets › Health Care › ELDN

Eledon Pharmaceuticals Inc. (ELDN)

ELDN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.97
-6.86% on the day
Market cap
$166.4M
Micro cap
Revenue
No annual revenue filed since the period ending 2016-12-31
Net income
No annual revenue filed since the period ending 2016-12-31

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerELDN on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2014
SEC CIK0001404281
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials

No annual revenue filed since the period ending 2016-12-31.

Warning signs

Cash runway
1.1 months
$6.9M cash at September 30, 2026
Share count, 1 year
+40.9%
2025-11-07 to 2026-11-10 · +249.0% over 3 years
Going-concern doubt
Yes
10-Q filed November 12, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"Based on these conditions and events that are known and reasonably knowable as of the date these condensed consolidated financial statements are issued, management has concluded that substantial doubt exists about the Company's ability to continue as a going concern."
10-Q 2026-11-12
Cash and burn$6.9M cash; operating cash flow -$19.6M a quarter.Report 2026-09-30
Shares outstanding84,459,713 (2026-11-10); 59,932,212 a year earlier; 24,198,130 three years earlier.Cover page 2026-11-10
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-05-01
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorDeloitte & Touche LLP, Costa Mesa, California, United States; changed auditors 2 times in 24 months8-K 4.01 2025-04-14
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$3.9M-$19.0M$6.9MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q2 2026
2026-06-30
Not filed-$31.6M-$22.7M$6.8MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q1 2026
2026-03-31
Not filed-$39.0M-$22.6M$6.2MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q4 2025
2025-12-31
Not filed-$10.4M-$14.1M$22.8MNo debt tagsNeeds four quarters10-K 2026-03-19
Q3 2025
2025-09-30
Not filed-$17.5M-$14.5M$3.7MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q2 2025
2025-06-30
Not filed-$11.2M-$17.7M$5.7MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q1 2025
2025-03-31
Not filed-$6.5M-$16.1M$8.5MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q4 2024
2024-12-31
Not filed-$44.6M-$19.0M$20.5MNo debt tagsNeeds four quarters10-K 2026-03-19

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-32026-05-01
Latest annual report10-K2026-03-19
Latest quarterly / interim10-Q2026-11-12
Latest current report8-K2026-11-12
Latest proxyDEFA14A2026-04-30

Source: SEC EDGAR submissions feed, 617 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-18.8%
1 month-9.6%
3 months-42.8%
Year to date+40.1%
1 year+20.2%
From 52-week high-49.8%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
PRQRProQR Therapeutics N.V.$1.18-16.31%$166.5M
PYXSPyxis Oncology Inc.$1.41-10.76%$168.6M
ORMPOramed Pharmaceuticals Inc.$3.90+5.12%$169.6M
ANTXAN2 Therapeutics Inc.$4.47-1.76%$169.6M
ADCTADC Therapeutics SA Common Shares$1.25-6.72%$159.7M
IFRXInflaRx N.V.$1.18+0.85%$173.9M
BBOTBridgeBio Oncology Therapeutics Inc. Common Stock$1.98-7.48%$158.9M
KRROKorro Bio Inc.$12.71-6.61%$174.5M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier